Angew Chem Int Ed Engl. 2012 Jan 23;51(4):941-4. doi: 10.1002/anie.201106527. Epub 2011 Dec 15.
A traceless vascular-targeting antibody-drug conjugate for cancer therapy
Bernardes GJ, Casi G, Trüssel S, Hartmann I, Schwager K, Scheuermann J, Neri D.
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang-Pauli Str. 10, 8093 Zürich (Switzerland)
Link to PubMed
Right on target: A chemically defined vascular-targeting antibody-drug conjugate (ADC) that offers comprehensive tumor coverage has been developed. When injected intravenously, this ADC potently inhibited tumor growth in a syngeneic immunocompetent model of murine cancer which cannot be cured by conventional cytotoxic agents.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.